|
Aug 1
|
New Strong Sell Stocks for August 1st
|
|
Jul 29
|
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
|
|
Jul 29
|
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
|
|
Jul 28
|
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
|
|
Jul 27
|
Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years ago
|
|
Jul 25
|
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
|
|
Jul 23
|
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
|
|
Jul 17
|
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
|
|
Jun 16
|
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
|
|
May 9
|
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
|
|
May 7
|
Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 7
|
Castle Biosciences Celebrates Skin Cancer Awareness Month
|
|
May 6
|
Q1 2025 Castle Biosciences Inc Earnings Call
|
|
May 6
|
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
|
|
May 5
|
Castle Biosciences Reports First Quarter 2025 Results
|
|
May 5
|
Castle Biosciences to Acquire Previse
|
|
May 2
|
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
|
|
Feb 24
|
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
|
|
Feb 20
|
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Feb 20
|
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
|